Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Danube Pharmaceuticals, Inc.
To evaluate the efficacy of four dosages of mg DNB-001 administered twice daily (bid) per os (p.o.) as an anti-ocular hypertensive agent, compared with placebo administered bid po, for 28 days, in patients with ocular hypertension.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, at least 18 years old, in general good health, not presently treated for elevated intraocular pressure (IOP), with best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity score equivalent to a Snellen score of 20/50 or better in each eye and lOP of 21 to 29 mm Hg at baseline.
You may not be if
Use of intraocular pressure lowering medication within the past 3 months or any history of ocular surgery for glaucoma
Evidence of potential angle closure by gonioscopy
Abnormal optic disc or visual field consistent with glaucoma
Use of topical ocular medications during the study and any evidence of systemic disease that might interfere with the conduct of the study.
Clareo Health | Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure
